Primary Sclerosing Cholangitis (PSC)

Welcome to the online home of the Chris M. Carlos and Catherine Nicole Jockisch Carlos Endowment for Primary Sclerosing Cholangitis (PSC). Thanks to support provided by this endowment, dedicated Mayo Clinic investigators and their teams are making strides to better understand and treat PSC patients, with the ultimate goal of developing a cure for this disease.

Follow the PSC page and stay up-to-date as we post news about advances in PSC research, clinical trials, and available resources.

PUBLIC PAGE
Nov 4, 2019

Bile Acid Profiles in Primary Sclerosing Cholangitis Predict Advancement of Disease

By Konstantinos N. Lazaridis, M.D. @klazaridis
Meaningful and reliable predictors of disease progression in PSC are currently lacking despite efforts over the past three decades. Patients with PSC often demonstrate increased plasma bile acids (BA) concentrations due to ongoing cholestasis, a hallmark of the disease. However, the relationship between composition of the BA in blood [...]
Bile Acid Profiles in Primary Sclerosing Cholangitis Predict Advancement of Disease
Oct 21, 2019

Understanding the Mechanism of Aging Cholangiocytes in PSC

By Konstantinos N. Lazaridis, M.D. @klazaridis
Aging (senescent) bile duct cells , i.e., cholangiocytes, demonstrate an arrest of the cell cycle, hypersecretion of inflammatory molecules and resistance to cell death. O’Hara et al., previously reported that aging of cholangiocytes is a feature in PSC patients, and that this event is regulated by a central molecular [...]
Understanding the Mechanism of Aging Cholangiocytes in PSC
Oct 7, 2019

Primary Sclerosing Cholangitis: Interpreting your Tests

By Ethan McConkey, Moderator @ethanmcconkey
About 50 percent of patients with Primary Sclerosing Cholagnitis (PSC) have no symptoms. Yet, patients with PSC have abnormal laboratory tests, which fluctuate over time and even normalize at times. Understanding the meaning and significance of liver testing and other procedures in PSC is important for the empowered patient. [...]
Primary Sclerosing Cholangitis: Interpreting your Tests
Sep 23, 2019

Biochemical and Imaging Biomarkers in PSC

By Konstantinos N. Lazaridis, M.D. @klazaridis
Primary Sclerosing Cholangitis (PSC) is a slowly progressing liver disease that lacks an ideal biomarker, which could predict disease progression. A biomarker is a measurable indicator of the presence or severity of a disease state. For example, body temperature is a biomarker of fever. In this presentation, Dr. John [...]
Biochemical and Imaging Biomarkers in PSC
Sep 9, 2019

Mayo Clinic PSC Abstracts Accepted for the 2019 Annual AASLD meeting

By Konstantinos N. Lazaridis, M.D. @klazaridis
The American Association for the Study of Liver Disease (AASLD) is the leading society of scientists and health care professionals in the United States committed to preventing, diagnosing, and treating liver disease. During the annual AASLD meeting that will take place in Boston, MA (November 8-12, 2019) our group [...]
Mayo Clinic PSC Abstracts Accepted for the 2019 Annual AASLD meeting

Invite Others

Send an email to invite people you know to join the Primary Sclerosing Cholangitis (PSC) page.

Please login or register to send an invite.